Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vardenafil.

Douglas Ormrod1, Stephanie E Easthope, David P Figgitt

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|May 25, 2002
PubMed
Summary
This summary is machine-generated.

Vardenafil, a PDE5 inhibitor, effectively treats erectile dysfunction (ED) by increasing blood flow for erections. Clinical trials show significant improvements in erectile function and intercourse success rates compared to placebo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.

Drugs·2006
Same author

0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain.

Drugs·2006
Same author

Rotigotine: in Parkinson's disease.

CNS drugs·2005
Same author

Darbepoetin alfa: its use in anemia associated with chronic kidney disease.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2005
Same author

Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections.

PharmacoEconomics·2005
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Area of Science:

  • Pharmacology
  • Urology
  • Andrology

Background:

  • Erectile dysfunction (ED) affects men of all ages and etiologies.
  • Phosphodiesterase type 5 (PDE5) inhibitors offer a pharmacological approach to managing ED.
  • Vardenafil is a selective PDE5 inhibitor designed to improve erectile function.

Purpose of the Study:

  • To evaluate the efficacy and safety of vardenafil in treating men with erectile dysfunction.
  • To assess the impact of vardenafil on erectile rigidity, duration, and successful intercourse.
  • To compare vardenafil's effectiveness across different patient populations, including those with diabetes and post-prostatectomy.

Main Methods:

  • Multiple randomized, placebo-controlled trials were conducted.
  • Patients received varying doses of vardenafil (5, 10, or 20mg) or placebo as needed.

Related Experiment Videos

  • Efficacy was assessed using the International Index of Erectile Function (IIEF) and a Global Assessment Question (GAQ).

    • Main Results:

    • Vardenafil significantly improved IIEF scores and GAQ responses compared to placebo across trials.
    • Erection rigidity and duration were notably enhanced in vardenafil recipients.
    • Successful intercourse attempts with ejaculation were significantly higher in vardenafil groups (71-75%) versus placebo (39.5%).

    Conclusions:

    • Vardenafil is an effective treatment for men with mild to severe erectile dysfunction, including those with diabetes or post-prostatectomy.
    • The drug demonstrates a favorable efficacy profile with generally mild to moderate, dose-dependent adverse events.
    • Vardenafil offers a significant improvement in erectile function and patient-reported outcomes for ED management.